Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
OCTOBER 11, 2023
The selections feature topics ranging from a review of the regulatory consequences of the FDA’s accelerated approval of eteplirsen, to a comparison of the safety and effectiveness of generic and brand-name fluticasone-salmeterol for COPD, to an analysis of free speech challenges to Medicare drug price negotiation under the Inflation Reduction Act.
Let's personalize your content